SurePac Protein RP MDi columns

Summary of SurePac Protein RP MDi Columns (Product Manual)

Significance of the topic

The SurePac Protein RP MDi stationary phase and column family are designed to address critical analytical challenges for therapeutic protein characterization, particularly monoclonal antibodies (mAbs), mAb subunits, fragments, bispecifics and antibody–drug conjugates. High-resolution reversed-phase separations that are compatible with mass-spectrometry-friendly mobile phases accelerate intact-mass workflows, subunit-level analysis and high-throughput QC, reducing time-to-answer compared with multi-step peptide-mapping approaches.

Objectives and overview of the manual

The product manual documents the column design (2.5 µm monodisperse polymer particles), recommended operating conditions, conditioning and care procedures, method examples for intact and subunit mAb separations, LC–MS compatibility, robustness and comparison with legacy phases. The aim is to guide users through optimal setup, conditioning, troubleshooting and to demonstrate performance (resolution, carryover, loading, ruggedness, lot-to-lot reproducibility) with representative data using NISTmAb model experiments.

Methodology and key procedural highlights

- Stationary phase and hardware: supermacroporous, monodisperse 2.5 µm polymer particles packed into hydrophobically coated stainless-steel hardware to minimize secondary metal interactions and unspecific adsorption.
- Mobile-phase chemistry: MS-friendly solvents (acetonitrile, isopropanol) with acidic modifiers; 0.1% TFA recommended for LC/UV work and up to 0.1% formic acid (FA) for LC–MS to increase ionization efficiency while accepting modest loss of chromatographic resolution.
- Typical column conditioning: gradual flow ramping to avoid bed disturbance, initial solvent flush (30 min) and optionally 2–3 overload injections to stabilize performance.
- Typical method parameters demonstrated: elevated column temperatures (70–80 °C) to improve mAb separations; example analytical format uses 2.1 × 50 mm column at 0.4 mL/min with 10- and 4-minute gradients for NISTmAb.
- Recommended operating envelopes: column temperatures 5–90 °C (typical protein separations 70–80 °C); pH stability: 2–12 for 2.1 mm columns and 2–10 for 0.3 mm columns; pressure limits depend on format (≈6500 psi for 2.1 mm, ≈8000 psi for 0.3 mm). Flow- and pressure-specific recommendations are provided for each dimension.

Used instrumentation

- LC systems: biocompatible/inert UHPLC systems with low dead volume (examples: Vanquish Horizon, Vanquish Flex, Vanquish Neo for low-flow). Use high-pressure mixing pumps for analytical formats to minimize gradient delay.
- Connectors and flow path: Viper or nanoViper fingertight fittings (100 µm ID recommended for small-bore connections); torque wrench recommended for reproducible attachment of 0.3 × 50 mm columns.
- Mass spectrometers and software used in examples: Orbitrap Exploris 480 and Q Exactive BioPharma platforms; acquisition and data analysis with Xcalibur, Freestyle and BioPharma Finder.

Main results and discussion

- Resolution and gradient optimization: a 10-minute gradient provided higher resolution for closely eluting mAb variants compared to a 4-minute high-throughput gradient; the faster gradient still separated major variants adequately, illustrating a trade-off between throughput and resolving power.
- Loading capacity: dynamic loading tests on 2.1 × 50 mm with NISTmAb showed sharp peaks and good variant resolution at low loads (0.5–1 µg). Peak broadening and reduced resolution were observed at higher loads (≥2 µg), consistent with onset of overloading and mass-transfer limitations for large proteins.
- Carryover and ruggedness: stationary phase demonstrated very low carryover; blank injections following high-mass loads showed no detectable residual signal. A 2.1 × 50 mm column maintained consistent retention and peak width over 500 injections, indicating strong ruggedness for routine use.
- Lot-to-lot reproducibility: analyses across three media lots using a 3-protein mix produced highly consistent retention times and peak widths, reflecting the uniformity of the monodisperse packing technology.
- Comparison to legacy phases: SurePac Protein RP MDi (2.5 µm) showed improved variant separation and peak definition versus larger-particle MAbPac RP (4 µm), supporting enhanced resolution for complex mAb profiles.
- LC–MS performance: coupling with Orbitrap-class MS using FA-based mobile phases allowed intact mass and subunit identification. Intact NISTmAb deconvolutions identified multiple glycoforms and common modifications (C-terminal lysine clipping, N-terminal pyroglutamate); measured masses were within a few ppm of theoretical values. Reduced (DTT) and IdeS-digested subunit analyses provided orthogonal confirmation and allowed improved localization of modifications.

Benefits and practical applications

- High-resolution intact and subunit separations facilitate rapid characterization of mAb heterogeneity, glycoform distribution and common PTMs without complete peptide mapping.
- Compatibility with MS-friendly mobile phases enables direct LC–MS workflows for intact mass, subunit and top-down strategies, accelerating biopharma characterization and QC.
- Low carryover, strong ruggedness and lot-to-lot reproducibility support routine laboratory use, stability studies and high-throughput QC environments.
- Multiple column formats (analytical and low-flow) allow adaptation to both standard UHPLC and micro/nano LC–MS platforms for sensitive intact-mass or top-down experiments.

Future trends and potential applications

- Increased integration with high-resolution MS workflows (native MS, top-down proteomics) for deeper proteoform-level characterization.
- Method standardization for regulatory QC, including validated high-throughput assays for release testing and stability indicating methods.
- Further miniaturization and optimization for nano- and micro-flow LC–MS to improve sensitivity for low-abundance biopharma samples and peptide sequencing workflows.
- Improvements to stationary-phase chemistries to expand native-compatible separations and reduce denaturing effects while preserving resolution.
- Greater automation in sample preparation and inline digestion (IdeS) for streamlined subunit analysis pipelines.

Conclusion

The SurePac Protein RP MDi column family provides a robust, MS-compatible reversed-phase solution for high-resolution separation of therapeutic proteins. Monodisperse polymer particles and engineered hardware deliver reproducible packing, low carryover and strong lot-to-lot consistency. Demonstrated performance for intact-mAb, reduced and IdeS-digested subunit workflows—combined with compatibility with Orbitrap-class mass spectrometers—makes these columns suitable for characterization, QC and high-throughput biopharma applications. Users should optimize gradient, temperature and loading for each analyte and follow recommended conditioning and cleaning protocols to maximize column lifetime.

References

• Thermo Fisher Scientific. SurePac Protein RP MDi product manual and Certificates of Analysis; part numbers for formats: 0.3 × 50 mm (43722-050332), 2.1 × 20 mm (43722-022132), 2.1 × 50 mm (43722-052132), 2.1 × 100 mm (43722-102132). Document ID/marketing reference XX004612-EN 0626 (product manual content summarized herein).
• Instrumentation and software cited in examples: Thermo Scientific Vanquish UHPLC systems, Orbitrap Exploris 480, Q Exactive BioPharma platform, Xcalibur, Freestyle and BioPharma Finder.